Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market
Porton Advanced, a subsidiary of Porton Pharma Solutions, Ltd, announced a strategic partnership with T&L...
Porton Advanced, a subsidiary of Porton Pharma Solutions, Ltd, announced a strategic partnership with T&L...
Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly...
Xellsmart, a Suzhou‑based stem‑cell startup, announced regulatory clearance from both China’s NMPA and the US...
YolTech Therapeutics, a China‑based mRNA therapy and gene therapy developer, announced a strategic partnership with...
Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ: ACLX) for USD 115.00...
CARsgen Therapeutics Holdings Ltd. (HKG: 2171), a China-based CAR-T cell therapy specialist, announced plans to invest...
Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug...
Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the National Medical Products Administration (NMPA) has approved...
Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...
AbelZeta Pharma, Inc. (Sino‑US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ: AZN) granting AZ the...
Fresenius Kabi and TQ Therapeutics announced a strategic‑development agreement granting Fresenius Kabi exclusive rights to...
Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences/Kite...
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation...
CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP‑11,...
The FDA’s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle‑based approach to...
Novabio Therapeutics, a China‑based clinical‑stage biotech, announced the successful completion of first patient dosing in...
The Cell and Gene Therapy Innovation and Transformation Center was officially established at Beijing Friendship...